VYNE Therapeutics Inc. (VYNE)

Market Cap	34.82M
Revenue (ttm)	424,000
Net Income (ttm)	-28.45M
Shares Out	14.10M
EPS (ttm)	-2.78
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	76,764
Open	2.520
Previous Close	2.570
Day's Range	2.410 - 2.800
52-Week Range	1.670 - 8.730
Beta	1.46
Analysts	Strong Buy
Price Target	7.38 (+198.79%)
Earnings Date	May 9, 2024

About VYNE

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company w...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 25, 2018
• Employees: 10
• Stock Exchange: NASDAQ
• Ticker Symbol: VYNE

Financial Performance

In 2023, VYNE's revenue was $424,000, a decrease of -11.11% compared to the previous year's $477,000. Losses were -$28.45 million, 22.6% more than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for VYNE stock is "Strong Buy." The 12-month stock price forecast is $7.38, which is an increase of 198.79% from the latest price.

Price Target

$7.38

(198.79% upside)

Analyst Consensus: Strong Buy